Clinical trials: Hypertension, Resistant
Pulmonary Hypertension
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT00370214
- Where
- 54 sites in United States
- Volunteers
- 3,515 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension.
- Trial name
- EPIMODE (NCT07761572)
- Testing
- CS1
- Volunteers
- 126 people
- Sponsor
- Cereno Scientific AB
Hypertension
Endovascular Carotid Body Ablation in Patients With Treatment- Resistant Hypertension: A Safety and Feasibility Study
This is a prospective, observational, multicenter trial to evaluate the safety and feasibility of selective endovascular unilateral carotid body ablation in patients with treatment-resistant hypertension.
- Trial name
- NCT02099851
- Testing
- Carotid body ablation (Cibiem)
- Where
- 2 sites in Czechia, Poland
- Volunteers
- 6 people
- Sponsor
- Noblewell
Hypertension
Carotid Body Removal for the Treatment of Resistant Hypertension: a Pilot Study
This is a pilot study to assess the effectiveness, safety and feasibility of carotid body removal in patients with high blood pressure (hypertension) resistant to medical treatment.
- Trial name
- NCT01729988
- Testing
- Carotid body excision
- Where
- Poland
- Volunteers
- 11 people
- Sponsor
- Noblewell
Hypertension, Cardiovascular Diseases
Global Paradise System US Post Approval Study
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood…
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- US GPS (NCT06297291)
- Testing
- Paradise Ultrasound Renal Denervation Treatment
- Where
- 46 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- ReCor Medical, Inc.
Resistant Hypertension
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with…
- Trial name
- NCT06526858
- Testing
- HyperQureTM Renal Denervation (RDN) System:
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- DeepQure Inc.
Renal Denervation, Resistant Hypertension
Renal Denervation by Allegro System in Patients With Resistant Hypertension
The purpose of ALLEGRO-HTN trial is to evaluate the safety and effectiveness of renal denervation in subjects with resistant hypertension by using Allegro renal denervation system
- Conditions
- Renal Denervation, Resistant Hypertension, Standard Medication
- Trial name
- NCT01874470
- Testing
- renal denervation, standard medication
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai AngioCare Medical
Hypertension
Device Based Therapy in Hypertension Trial
The purpose of this study is to demonstrate the safety and efficacy of the Rheos Baroreflex Hypertension Therapy System in patients with refractory hypertension.
- Trial name
- DEBuT-HT (NCT00710190)
- Testing
- Rheos Baroreflex Hypertension Therapy System
- Where
- 9 sites in Czechia, Germany and 4 more
- Volunteers
- 46 people
- Sponsor
- CVRx, Inc.
Resistant Hypertension
Treatment of Resistant Hypertension: Cohort Study
This is a multicenter, prospective observational cohort study. It will compare effectiveness and safety of various add-on treatment options in regard to arterial blood pressure control in adult patients with treatment resistant…
- Trial name
- TRYCORT (NCT05087940)
- Testing
- Add-on therapy
- Where
- 12 sites in Serbia
- Volunteers
- 731 people
- Sponsor
- Galenika AD Beograd
Hypertension,Essential
First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension
The carotid body is located at the bifurcation of the internal and external carotid arteries. It is a chemoreceptor that plays a role in the sympathetic nervous system and in the development and maintenance of hypertension.
- Trial name
- NCT03314012
- Testing
- Catheter-Based Carotid Body Ablation
- Where
- 7 sites in Australia, Czechia and 1 more
- Volunteers
- 39 people
- Sponsor
- Cibiem, Inc.
Hypertension
Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
The Study objective is to assess the performance of the Vessix V2 Renal Denervation System for the treatment of uncontrolled hypertension using an innovative percutaneous Radio Frequency (RF) balloon catheter renal denervation…
- Trial name
- REDUCE-HTN (NCT01541865)
- Testing
- Renal Denervation
- Where
- 26 sites in Australia, Austria and 6 more
- Volunteers
- 146 people
- Sponsor
- Boston Scientific Corporation
Resistant Hypertension
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC)…
- Trial name
- NCT05562934
- Testing
- XXB750 drug
- Where
- 78 sites in United States, Australia and 14 more
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Resistant Hypertension, Uncontrolled Hypertension
Rapid Renal Sympathetic Denervation for Resistant Hypertension II
This is a global, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation with the OneShot Renal Denervation System in patients with uncontrolled hypertension.
- Conditions
- Resistant Hypertension, Uncontrolled Hypertension, Renal Artery Ablation
- Trial name
- RAPID II (NCT01939392)
- Testing
- Renal Denervation (OneShot™ Renal Denervation System)
- Where
- Italy
- Sponsor
- Medtronic Endovascular
Hypertension With Metabolic Syndrome
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic…
- Trial name
- ALTO (NCT00542269)
- Testing
- Amlodipine, Aliskiren, Ramipril
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- Novartis
Hypertension
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
This is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States Food and Drug Administration (FDA), which means that…
- Trial name
- Darusentan (NCT00389779)
- Testing
- Darusentan, Guanfacine
- Where
- 147 sites in United States, Argentina and 8 more
- Volunteers
- 849 people
- Sponsor
- Gilead Sciences
Hypertension Resistant to Conventional Therapy, Bradycardia
Safety and Performance Study of the Moderato System
The purpose of the study is to evaluate the safety and performance of the Moderato System by implanting the Moderato pacemaker in patients who require a dual chamber pacemaker, and who also have hypertension, in order to reduce…
- Conditions
- Hypertension Resistant to Conventional Therapy, Bradycardia, Atrioventricular Block
- Trial name
- NCT02282033
- Testing
- The Moderato System
- Where
- 10 sites in Austria, Chile and 5 more
- Volunteers
- 57 people
- Sponsor
- BackBeat Medical Inc
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes
The purpose of this study is to investigate (1) the effect of topiramate on insulin sensitivity in overweight or obese patients with type 2 diabetes mellitus and (2) the safety of topiramate in type 2 diabetic patients.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00236626
- Testing
- topiramate
- Volunteers
- 38 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Patients, Resistant Hypertension
Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.
- Trial name
- NCT02515331
- Testing
- LHW090
- Where
- 16 sites in United States, Denmark and 4 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Renal
RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157
This is a prospective, multi-center, non-randomized, feasibility study to assess the safety and effectiveness of renal artery sympathetic denervation using the investigational devices in subjects with resistant hypertension.
- Trial name
- RENABLATE-II (NCT02095691)
- Testing
- Celsius® ThermoCool® Renal Denervation
- Volunteers
- 19 people
- Sponsor
- Biosense Webster, Inc.
Hypertension Resistant to Conventional Therapy
A Study to Evaluate Safety and Efficacy of the Redy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension
The ReDy™ System (Renal Dynamics) is a renal denervation device incorporating a variety of ablation features and technical improvements over previously designed systems into a single product.
- Trial name
- NCT02690909
- Testing
- Redy™ Renal Denervation System
- Where
- 10 sites in Belgium, Germany and 6 more
- Volunteers
- 55 people
- Sponsor
- Renal Dynamics GmbH